Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 36

1.

Efficacy and safety of insulin in type 2 diabetes: meta-analysis of randomised controlled trials.

Erpeldinger S, Rehman MB, Berkhout C, Pigache C, Zerbib Y, Regnault F, Guérin E, Supper I, Cornu C, Kassaï B, Gueyffier F, Boussageon R.

BMC Endocr Disord. 2016 Jul 8;16(1):39. doi: 10.1186/s12902-016-0120-z.

2.

Efficacy and Safety of LixiLan, a Titratable Fixed-Ratio Combination of Lixisenatide and Insulin Glargine, Versus Insulin Glargine in Type 2 Diabetes Inadequately Controlled on Metformin Monotherapy: The LixiLan Proof-of-Concept Randomized Trial.

Rosenstock J, Diamant M, Aroda VR, Silvestre L, Souhami E, Zhou T, Perfetti R, Fonseca V; LixiLan PoC Study Group..

Diabetes Care. 2016 Sep;39(9):1579-86. doi: 10.2337/dc16-0046. Epub 2016 Jun 9.

PMID:
27284114
3.

Glycemic control and adherence to basal insulin therapy in Taiwanese patients with type 2 diabetes mellitus.

Chien MN, Chen YL, Hung YJ, Wang SY, Lu WT, Chen CH, Lin CL, Huang TP, Tsai MH, Tseng WK, Wu TJ, Ho C, Lin WY, Chen B, Chuang LM.

J Diabetes Investig. 2016 Nov;7(6):881-888. doi: 10.1111/jdi.12532. Epub 2016 May 30.

4.

Triple therapy in type 2 diabetes; a systematic review and network meta-analysis.

Downes MJ, Bettington EK, Gunton JE, Turkstra E.

PeerJ. 2015 Dec 7;3:e1461. doi: 10.7717/peerj.1461. eCollection 2015.

5.

How much is too much? Outcomes in patients using high-dose insulin glargine.

Reid T, Gao L, Gill J, Stuhr A, Traylor L, Vlajnic A, Rhinehart A.

Int J Clin Pract. 2016 Jan;70(1):56-65. doi: 10.1111/ijcp.12747. Epub 2015 Nov 13.

6.

Comparison between the therapeutic effect of metformin, glimepiride and their combination as an add-on treatment to insulin glargine in uncontrolled patients with type 2 diabetes.

Park CY, Kang JG, Chon S, Noh J, Oh SJ, Lee CB, Park SW.

PLoS One. 2014 Mar 10;9(3):e87799. doi: 10.1371/journal.pone.0087799. eCollection 2014.

7.

Standard and Novel Treatment Options for Metabolic Syndrome and Diabetes Mellitus.

Groves EM, Yu K, Wong ND, Malik S.

Curr Treat Options Cardiovasc Med. 2013 Nov 15. [Epub ahead of print]

8.

Effects of adding linagliptin to basal insulin regimen for inadequately controlled type 2 diabetes: a ≥52-week randomized, double-blind study.

Yki-Järvinen H, Rosenstock J, Durán-Garcia S, Pinnetti S, Bhattacharya S, Thiemann S, Patel S, Woerle HJ.

Diabetes Care. 2013 Dec;36(12):3875-81. doi: 10.2337/dc12-2718. Epub 2013 Sep 23.

9.

Intensification of insulin therapy for type 2 diabetic patients in primary care: basal-bolus regimen versus premix insulin analogs: when and for whom?

Mosenzon O, Raz I.

Diabetes Care. 2013 Aug;36 Suppl 2:S212-8. doi: 10.2337/dcS13-2007. Review. No abstract available.

10.

Diabetes: glycaemic control in type 2 (drug treatments).

Gorter KJ, van de Laar FA, Janssen PG, Houweling ST, Rutten GE.

BMJ Clin Evid. 2012 Oct 11;2012. pii: 0609. Review.

11.
12.

Long-Acting Insulin Analogues for the Treatment of Diabetes Mellitus: Meta-analyses of Clinical Outcomes.

Canadian Agency for Drugs and Technologies in Health (CADTH)..

CADTH Technol Overv. 2010;1(1):e0113. Epub 2010 Mar 1. No abstract available.

13.

Management of hyperglycemia in type 2 diabetes: a patient-centered approach: position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD).

Inzucchi SE, Bergenstal RM, Buse JB, Diamant M, Ferrannini E, Nauck M, Peters AL, Tsapas A, Wender R, Matthews DR; American Diabetes Association (ADA).; European Association for the Study of Diabetes (EASD)..

Diabetes Care. 2012 Jun;35(6):1364-79. doi: 10.2337/dc12-0413. Epub 2012 Apr 19. Review. No abstract available. Erratum in: Diabetes Care. 2013 Feb;36(2):490.

14.

Fasting plasma glucose 6-12 weeks after starting insulin glargine predicts likelihood of treatment success: a pooled analysis.

Karl D, Zhou R, Vlajnic A, Riddle M.

Diabet Med. 2012 Jul;29(7):933-6. doi: 10.1111/j.1464-5491.2012.03640.x.

15.

Comparing the effects of insulin glargine and thiazolidinediones on plasma lipids in type 2 diabetes: a patient-level pooled analysis.

Chaudhuri A, Rosenstock J, DiGenio A, Meneghini L, Hollander P, McGill JB, Dandona P, Ilgenfritz J, Riddle M.

Diabetes Metab Res Rev. 2012 Mar;28(3):258-67. doi: 10.1002/dmrr.1305.

16.

The role of GLP-1 mimetics and basal insulin analogues in type 2 diabetes mellitus: guidance from studies of liraglutide.

Barnett AH.

Diabetes Obes Metab. 2012 Apr;14(4):304-14. doi: 10.1111/j.1463-1326.2011.01523.x. Epub 2011 Dec 22. Review.

17.
18.

An analysis of early insulin glargine added to metformin with or without sulfonylurea: impact on glycaemic control and hypoglycaemia.

Fonseca V, Gill J, Zhou R, Leahy J.

Diabetes Obes Metab. 2011 Sep;13(9):814-22. doi: 10.1111/j.1463-1326.2011.01412.x.

19.

Supplemental Content

Support Center